In vitro effective dose (ED99) against CPV-2 was demonstrated at 100μg/mL in FK81 cells
Field trial demonstrated improved survivability of naturally infected puppies aged between 8 weeks and 12 weeks with hpCPV-2 strain from 30% (untreated group) to 80% effective 8th day post-treatment by RetroMAD1 orally at 0.6mg/kg until recovery thrived. The trial was published in April 2013 (Thesis by Dr Juan Carlos Peralta at the College of Veterinary Medicine, De La Salle-Araneta University of the Philippines)
